Rabies vaccine - GlaxoSmithKline

Drug Profile

Rabies vaccine - GlaxoSmithKline

Alternative Names: KD-357; Purified chicken-embryo cell rabies vaccine; RabAvert; Rabipur; Rabivac; Rasilvax

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer GlaxoSmithKline; Kaketsuken; Sanofi
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rabies

Most Recent Events

  • 09 Dec 2016 GlaxoSmithKline plans an extension phase IV trial for Rabies in China (IM) (NCT02991872)
  • 01 Aug 2015 Novartis completes a phase III trial for Rabies in Philippines & Thailand (NCT02177032)
  • 02 Jul 2015 Novartis initiates a phase III trial for Rabies in Austria (EudraCT2015-000382-31)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top